Gen-Probe requests US approval of Procleix Ultrio for hepatitis B virus screening
This article was originally published in Clinica
Executive Summary
Gen-Probe has applied to the US FDA for approval to use its Procleix Ultrio assay to screen donated blood for the hepatitis B virus (HBV). The San Diego, California company has submitted a supplemental biologics licence application (BLA) to use the assay to screen for HBV on both its semi-automated instrument platform and on the fully automated, high-throughput Tigris system. The FDA approved Procleix Ultrio to screen donated blood for HIV-1 and the hepatitis C virus (HCV) in late 2006. According to the World Health Organisation, more than 350 million people worldwide are chronically infected with HBV, with more than one million dying every year from the disease. Gen-Probe's blood screening products are marketed worldwide by Chiron, a subsidiary of pharma giant Novartis.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.